Here are worldwide third-quarter sales figures for some key Pfizer prescription drugs. Except for Enbrel and Prevnar, the decreases are due to generic competition.
PRODUCT NAME MAIN CONDITION/USE 3Q 2012 SALES 3Q 2011 SALES PERCENT CHANGE
Lipitor High cholesterol $749 million $2.6 billion down 71 percent
Lyrica Fibromyalgia/pain $1.04 billion $961 million up 8 percent
Enbrel (outside U.S.) Rheumatoid arthritis $893 million $957 million down 7 percent
Prevnar 13 Pneumococcal vaccine $868 million $1.01 billion down 14 percent
Celebrex Pain $676 million $643 million up 5 percent
Viagra Erectile dysfunction $517 million $493 million up 5 percent
Norvasc High blood pressure $319 million $350 million down 9 percent
Zyvox MRSA infections $328 million $321 million up 2 percent
Sutent Multiple cancers $294 million $298 million down 1 percent
Premarin/Prempro Menopause symptoms $262 million $267 million down 2 percent
Source: Pfizer Inc.
Former Speaker Dennis Hastert Indicted For Lying To The FBI, Evading Currency Transaction Reports | Matt Vespa
Fifteen Dollars an Hour for Thee, but Not for Me: California Unions Request Exemption from New Wage Law | Christine Rousselle